EDEN PRAIRIE, Minn., March 04, 2021 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, will ...

EDEN PRAIRIE, Minn., Sept. 20, 2018 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq:CHFS) announced today results from a poster recently presented by a United Kingdom’s National Health Service ...

EDEN PRAIRIE, Minn., July 16, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to improving the lives of patients suffering from fluid overload, today ...

Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of ...

Credit: scPharmaceuticals. Previously, the novel furosemide delivery system was only indicated for congestion due to fluid overload in adult patients with NYHA Class II and Class III CHF. The Furoscix ...

Please provide your email address to receive an email when new articles are posted on . scPharmaceuticals Inc. announced the FDA approved its self-administered subcutaneous furosemide injection for ...

The U.S. Food and Drug Administration (FDA) has approved Lasix ONYU (furosemide injection), a new drug-device combination ...

Please provide your email address to receive an email when new articles are posted on . Patients with chronic kidney disease and fluid overload are at risk for cardiovascular events and kidney disease ...

ENBUMYST™ is the first and only intranasal loop diuretic approved in the U.S. offering a self-administered alternative between oral and intravenous diuretics. Edema and fluid overload remain the ...